drugset
drugset / Trial / NCT05057013

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

NCT05057013 ↗

Phase 1/2 Active not recruiting 81 enrolled Cancer Research UK Hummingbird Bioscience · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours. The main aims are to find out the best dose of HMBD-001 that can be given to participants alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how they can be treated, and what happens to HMBD-001 inside the body and how it affects cancer cells.

Timeline

Start
2021-11-10
Primary completion
2025-11
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg —
Subject NEZUTATUG Monoclonal antibody — Intravenous

Indications

castration-resistant prostate carcinoma cervical cancer colorectal cancer endometrial cancer esophageal cancer gastric cancer head and neck squamous cell carcinoma hepatocellular carcinoma malignant pancreatic neoplasm melanoma non-small cell lung carcinoma ovarian cancer triple-negative breast carcinoma urinary bladder cancer